Co-Diagnostics Inc. (CODX)
NASDAQ NASDAQ Primary 
LSE 
Co-Diagnostics, Inc. (CODX) Shareholder/Analyst Call Transcript
Co-Diagnostics, Inc. (CODX) Shareholder/Analyst Call Transcript
Co-Diagnostics, Inc. (CODX) Q2 2026 Earnings Call Transcript
Co-Diagnostics, Inc. (CODX) Q2 2026 Earnings Call Transcript
Is Co-Diagnostics National Security's Next Diagnostic Pick?
A structural shift is underway in the biodefense landscape. The declaration of a Public Health Emergency of International Concern (PHEIC) by the World Health Organization on May 17, 2026, for the Bundibugyo virus Ebola outbreak should be seen by investors as more than a headline, because it is a fundamental catalyst.
Co-Diagnostics, Inc. (CODX) Q1 2026 Earnings Call Transcript
Co-Diagnostics, Inc. (CODX) Q1 2026 Earnings Call Transcript
Co-Diagnostics, Inc. (CODX) Q4 2025 Earnings Call Transcript
Co-Diagnostics, Inc. (CODX) Q4 2025 Earnings Call Transcript
CODX Shares Dip Despite Australian Patent Grant for Co-Dx PCR Platform
CoDiagnostics secures its first patent for the Co-Dx PCR platform in Australia, strengthening IP protection as the point-of-care system awaits regulatory clearance.
CoDiagnostics (CODX) Upgraded to Buy: Here's What You Should Know
CoDiagnostics (CODX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Co-Diagnostics, Inc. (CODX) Q3 2025 Earnings Call Transcript
Co-Diagnostics, Inc. ( CODX ) Q3 2025 Earnings Call November 13, 2025 4:30 PM EST Company Participants Andrew Benson - Head of Investor Relations Dwight Egan - Chairman & CEO Brian Brown - CFO & Company Secretary Conference Call Participants Michael Okunewitch - Maxim Group LLC, Research Division Presentation Operator Hello, and thank you for standing by. My name is Tiffany, and I will be your conference operator today.
Co-Diagnostics, Inc. (CODX) Reports Q3 Loss, Misses Revenue Estimates
Co-Diagnostics, Inc. (CODX) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.32 per share a year ago.
Co-Diagnostics, Inc. (CODX) Discusses Saudi Arabia Joint Venture, AI Initiatives and Diagnostics Technology Developments Transcript
Co-Diagnostics, Inc. ( CODX ) Discusses Saudi Arabia Joint Venture, AI Initiatives and Diagnostics Technology Developments November 5, 2025 11:00 AM EST Company Participants Dwight Egan - Chairman & CEO Conference Call Participants Valter Pinto Presentation Valter Pinto Good morning, and welcome, everyone, to the Co-Diagnostics fireside chat. My name is Valter Pinto.
Co-Diagnostics, Inc. (CODX) Q2 2025 Earnings Conference Call Transcript
Co-Diagnostics, Inc. (NASDAQ:CODX ) Q2 2025 Earnings Conference August 14, 2025 4:30 PM ET Company Participants Andrew Benson - Head of Investor Relations Brian L. Brown - CFO & Company Secretary Dwight H.
Co-Diagnostics, Inc. (CODX) Reports Q2 Loss, Misses Revenue Estimates
Co-Diagnostics, Inc. (CODX) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to a loss of $0.25 per share a year ago.
